Last reviewed · How we verify
NK510
At a glance
| Generic name | NK510 |
|---|---|
| Also known as | No other name |
| Sponsor | Base Therapeutics (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of NK510 to Treat NSCLC (EARLY_PHASE1)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer (EARLY_PHASE1)
- NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus (NA)
- Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma (EARLY_PHASE1)
- Safety and Efficacy of NK510 to Treat Gastric Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NK510 CI brief — competitive landscape report
- NK510 updates RSS · CI watch RSS
- Base Therapeutics (Shanghai) Co., Ltd. portfolio CI